arrow
G

Geert D'Haens

amsterdam university medical centers
H指数:124
被引数:7.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI

静脉注射与皮下注射Guselkumab诱导:GALAXI 2 & 3和GRAVITI研究第12周和第96周疗效

2026-10-270
OAAI
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial

代谢功能障碍相关脂肪性肝炎中的 senolytics 达沙替尼和槲皮素:一项概念验证随机对照试验

2026-10-010
OAAI
Selective SII<2/SII<3 inhibition reprograms pro-and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes

选择性SII<2/SII<3抑制重编程骨髓细胞中的促炎和抗炎通路,改善自身免疫性疾病结局

2026-02-090
OA
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

阑尾切除术与改用JAK抑制剂诱导生物治疗失败 (COSTA) 后活动性溃疡性结肠炎患者缓解的比较: 一项多中心、前瞻性队列研究的1年结果

2026-01-060
PRE
Unsupervised Machine Learning to Identify Distinct Response Patterns to Guselkumab in Participants With Crohn's Disease: Post Hoc Analysis of the Pooled GRAVITI and GALAXI 2/3 Studies

基于无监督机器学习识别克罗恩病患者对Guselkumab的不同反应模式:GRAVITI和GALAXI 2/3研究的合并数据事后分析

2025-12-010
PRE
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn’s Disease

关于标准化评估肛门瘘性克罗恩病新型疗法临床试验操作的建议

2025-11-190
PRE
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial

SOR102的安全性及药代动力学研究,该药物是一种口服的双特异性抑制剂,可同时抑制TNF和interleukin-23,研究对象包括健康受试者和溃疡性结肠炎患者:一项首次人体、双盲、随机、安慰剂对照的I期临床试验。

2025-11-130
PRE
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease

在基线使用皮质类固醇的中度至重度活动性克罗恩病患者中,乌帕替尼的疗效与安全性。

2025-11-011
OAAI
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease

VICTRIVA研究的设计与原理:一项关于vedolizumab与upadacitinib联合治疗克罗恩病的随机、双盲、3b期研究

2025-11-010
OAAI
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease

炎症性肠病中先进联合治疗(ACT)临床试验设计的国际共识

2025-10-230
OAAI